Actively Developing and Expanding Ex Vivo Therapeutic Programs. 7 Growing Our Leadership Position in the Field of Genome Editing. Acute treatments are used to treat patients who are experiencing an attack. Our diverse product strategy includes multiple elements. On May 30, 2020, we entered into amendment no. We access these patent estates from licensors, including Caribou, Novartis and OSR. Patents issued from this family will expire in or after 2033, if successfully maintained. Many of these competitors may have access to greater capital and resources than us. Some preclinical testing may continue even after the IND is submitted. The FDA adjusts the PDUFA user fees on an annual basis. In addition, these designations may not provide us with a material commercial advantage. After a BLA is approved, the product also may be subject to official lot release. Compensation and Benefits, Health and Wellness. There can be no assurance we will be successful in solving any or all of these issues. All of our lead programs are still in the discovery, preclinical or early clinical stage. 45 Research and development of biopharmaceutical products is inherently risky. These laws impose criminal and civil penalties on violators. We will rely on third parties to conduct our clinical trials. Such an outcome could have a material adverse effect on our business in Europe.
